Background: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens.
INTRODUCTION
P orphyria cutanea tarda (PCT) is the most common human porphyria and is due to the deficiency of uroporphyrinogen decarboxylase (UROD) activity in hepatocytes. 1, 2 This enzyme deficiency results from an inhibitor that is generated in the presence of oxidative stress and in mild to moderately increased amounts of hepatic iron. 1, 3, 4 Susceptibility factors for PCT include alcohol use, smoking, hepatitis C virus (HCV) infection, hemochromatosis gene (HFE) mutations, estrogen use, human immunodeficiency virus infection and inherited UROD mutations.
1,2,5-9 PCT causes chronic cutaneous photosensitivity with blistering skin lesions on sunexposed areas. It is readily treatable either by repeated phlebotomy, which removes hepatic iron, or by a lowdose regimen of hydroxychloroquine (HCQ), which removes accumulated porphyrins from the liver, 7 and probably from other tissues.
HCV infection, which increases oxidative stress in hepatocytes and suppresses hepcidin production, thereby increasing iron absorption, is associated with 50-70% of PCT cases in the United States. 1, [5] [6] [7] 10, 11 There are no current guidelines regarding the treatment of HCV infection when associated with PCT. PCT is generally more symptomatic and needs treatment more urgently. Until recently, the treatment of HCV has been difficult and prolonged and not always successful, whereas the treatment of PCT is virtually always effective. Further, response to interferon-based therapy for HCV is better after reduction of hepatic iron, 12, 13 which is almost always elevated with active PCT. Therefore, it is generally advised to treat and achieve remission of PCT and then attempt to treat HCV infection. 1, 14 But with the advent of newer direct-acting antiviral agents (DAA), HCV treatment has become more rapid, effective and safe. 15 However, there is little published experience with any treatments for HCV in patients with PCT.
MATERIAL AND METHODS
Institutional Review Board approval was obtained at both the institutions as part of ongoing longitudinal study of the porphyria consortium.
We describe 13 patients with PCT who were selected because they underwent treatment for chronic HCV after or before the treatment of PCT. They underwent a total of 22 treatment courses for HCV. Of the 13 patients, 10 were treated at University of Texas Medical Branch and 3 at The University of Alabama. Their clinical features, susceptibility factors and porphyrin levels are summarized in Table 1 , and details of each HCV treatment regimen in Table 2 in the order of their first treatment for HCV. These patients would be classified as Type 1 (sporadic) PCT, because DNA studies showed that none had heterozygous UROD mutations (as found in Type 2 [familial] PCT), and none had a family history of the disease in the absence of a UROD mutation (as in Type 3 PCT). However, response to HCV treatment is not expected to be affected by the presence of a UROD mutation.
Patient 1
Patient was a white male who developed PCT at the age of 45 years and was effectively treated elsewhere with a total of 8 phlebotomies. He was also found to have HCV genotype 1b infection at that time. Other PCT susceptibility factors were alcohol use, smoking, heterozygous C282Y mutation of the HFE gene and iron overload (serum ferritin level of 1,471 ng/mL). He then failed 3 interferon plus ribavirin regimens elsewhere. After the second treatment attempt, PCT relapsed with a plasma porphyrin of 10.3 μg/dL and ferritin of 211 ng/ mL, which was treated successfully by phlebotomy. The third treatment was an investigational high-dose pegylated interferon (PEGIFN) plus ribavirin regimen that caused pancytopenia, weight loss and a recurrence of PCT, with a plasma porphyrin level of 11.8 μg/ dL and serum ferritin of 245 ng/mL. After this unsuccessful course of HCV treatment, he was enrolled in a PCT treatment study and achieved remission of PCT with low-dose HCQ 100 mg twice weekly. HCQ was then continued during an unsuccessful investigational treatment with interleukin 29 and ribavirin, and then also during a successful trial with a DAA elsewhere. HCQ was stopped after he achieved sustained viral response (SVR), and PCT has remained in remission for 5 years.
Patient 2
Patient was a white female who developed PCT at the age of 42 years, and was also found to have genotype 1 HCV infection acquired from previous intravenous drug abuse. Other PCT susceptibility factors included smoking (53 pack years) and alcohol use (half gallon of whiskey per day for 29 years). She had blisters and crusted lesions on the back of her hands, lower forearms, face and feet. Laboratory findings included HCV RNA 479,015 IU/mL, serum ferritin 201 ng/mL, plasma porphyrins 25.5 μcg/dL and urine porphyrins 9,703 nmol/L with a predominance of highly carboxylated porphyrins (Table 2) . Liver biopsy showed bridging fibrosis (stage 3 disease) without steatosis or excess iron. She was treated with HCQ 100 mg twice a week as a participant in a study comparing this treatment with phlebotomy. After achieving remission of PCT, she was started on PEGIFN and ribavirin for treating HCV infection. An early virologic response occurred at 3 months, but she developed blistering skin lesions with elevated plasma porphyrins of 19.2 μg/dL and urinary HCV, hepatitis C virus; HFE, hemochromatosis gene; PCT, porphyria cutanea tarda; WT, wild type. Reference ranges: plasma porphyrins, o0.9 μg/dL; total urine porphyrins o300 nmol/L; uroporphyrin and heptacarboxyl porphyrin, o30 and o5 percentage of the total, respectively.
porphyrins of 8,997 nmol/L (36% uroporphyrin, 50% heptacarboxyl porphyrin, 4% hexacarboxylporphyrin, 3% pentacarboxylporphyrin and 6% coproporphyrin). She remained abstinent of smoking and of alcohol use since the beginning of the treatment. She was hospitalized with pneumonia and pancytopenia (presumably due to PEGIFN) and HCV treatment was interrupted. After recovery from pneumonia, low-dose HCQ was started for PCT. Once PCT was in remission, the same HCV treatment was restarted and continued along with low-dose HCQ for 1 year. A SVR was achieved and PCT has remained in remission for 6 years. On follow-up after SVR, she remains abstinent of alcohol use but resumed smoking intermittently.
Patient 3
Patient was a white female with a history of intravenous drug use who was diagnosed with both PCT and chronic HCV infection genotype 1b at the age of 52 years after she developed blisters on the dorsal hands, face, arms and feet. Other susceptibility factors for PCT were alcohol use (about 9 drinks per week), smoking 1 pack per day since age 23, oral contraceptive use before hysterectomy at age 36 and replacement estrogen use after age 50. She was treated with low-dose HCQ treatment until plasma porphyrins were normal. HCQ was then continued during HCV treatment with PEGIFN and ribavirin. She achieved SVR, and PCT has also remained in remission for 4 years. 
Patient 4
Patient was a white female who developed PCT at the age of 49 years and was simultaneously found to have chronic HCV infection genotype 1a. PCT was treated successfully by repeated phlebotomy. Other susceptibility factors for PCT were absent. HCV was treated with PEGIFN and ribavirin at age 51, but was stopped after 2 months due to lack of response and relapse of PCT. At age 63, she was treated with sofosbuvir and simeprevir for 12 weeks without adverse effects or relapse of PCT. At the end of treatment, HCV RNA was undetectable and urine and plasma porphyrins were normal (132 nmol/L and 0.2 μg/dL, respectively) and have remained so for 2 years.
Patient 5
Patient was a white male with a history of excess use of alcohol who developed PCT at the age of 54 years with blistering lesions on the dorsal hands. He was also found to have chronic HCV genotype 1b infection. Remission of PCT was achieved after 7 biweekly phlebotomies of 450 mL each. At age 58, HCV treatment with PEGIFN and ribavirin was initiated. However, this was discontinued due to fatigue, thrombocytopenia and depression. At age 64, PCT was in remission (urine and plasma porphyrins of 42 nmol/L and 0.1 μg/dL, respectively) and there was no evidence of cirrhosis by clinical, biochemical and liver imaging evaluation. Treatment with sofosbuvir and simeprevir for 12 weeks achieved SVR, and PCT has remained in remission for 2 years.
Patient 6
Patient was a white male with a history of intravenous drug use who developed PCT at the age of 43 years when he presented with skin blisters and friability on the dorsal hands. Susceptibility factors for PCT included chronic HCV genotype 1b infection, heavy alcohol use and a heterozygous H63D mutation of the HFE gene. PCT was treated successfully by phlebotomies and he abstained from alcohol use. He resumed drinking 4-5 drinks per week from age 48-53, and then stopped again. Several recurrences of PCT, the last at age 53, were treated by phlebotomy. Liver biopsies at the age of 43 and 48 years showed stage 1 fibrosis, and a repeat biopsy at age 53 showed stage 3 fibrosis. He started therapy for HCV at age 54 with PEGIFN, ribavirin and telaprevir. He responded well with undetectable HCV RNA after 4 weeks of therapy. However, the development of migraines and pancytopenia required dose reduction and transfusion with 2 units of packed red blood cells. HCV relapsed and PCT recurred, with ferritin levels exceeding 1,000 ng/mL. PCT was retreated with phlebotomy. At age 57, he was retreated for HCV with sofosbuvir and simeprevir for 12 weeks, with no side effects. HCV RNA remains undetectable and PCT remains in remission with normal urine and plasma porphyrins for over 1 year.
Patient 7
Patient was a white male with a history of intravenous drug use who developed PCT at the age of 48 years with blisters and increased fragility on the dorsal hands and face. He was also found to have chronic HCV genotype 1a infection. PCT was treated by repeated phlebotomy, which achieved the target ferritin of o20 ng/mL, and urine and plasma porphyrin concentrations became normal. He was then treated with sofosbuvir and ledispavir for 24 weeks. He developed SVR, and PCT has not relapsed during 1 year of follow up.
Patient 8
Patient was a white male who developed friable skin and blisters on the dorsal hands and fingers at the age of 46 years, which worsened gradually. He was found to have PCT as well as chronic HCV genotype 1 infection at age 48. He drank about 15 drinks daily from age 19, and reduced to about 1 drink daily at age 48, smoked about 10 cigarettes daily since age 17 and was heterozygous for the H63D mutation of the HFE gene. PCT was treated with low-dose HCQ 100 mg twice weekly for 21 months, and his lesions cleared and did not recur. At age 49, he was continued on HCQ to prevent the recurrence of PCT during treatment with PEGIFN and ribavirin. HCV RNA has remained undetectable, and PCT has remained in remission after 5 years.
Patient 9
Patient was a white male with a history of intravenous drug use, heavy alcohol use and smoking who was found to have HCV genotype 2b infection at the age of 49 years. At age 59, he developed blisters, increased friability and milia that progressively worsened on the dorsal hands and right forearm. He stopped consuming alcohol but continued to smoke 1 pack per day, was heterozygous for the H63D mutation of the HFE gene and was taking carisoprodol for chronic musculoskeletal pain. Treatment with low-dose HCQ achieved remission of PCT. HCQ was continued during HCV treatment with sofosbuvir and ribavirin for 12 weeks. After 6 months of treatment, HCV RNA was undetectable and PCT also remained in remission.
Patient 10
Patient was an African American male with a history of jaundice at the age of 7 years, heavy alcohol intake (750 mL per day from age 20 until he stopped at age 62), a 1 pack per day history of smoking and noted friability of the skin on the dorsal hands beginning at age 55. At age 62, he was started on triple therapy (teleprevir, PEGIFN and ribavirin) for HCV genotype 2b infection. Hepatitis B surface antigen was positive, but hepatitis B virus DNA was negative. He developed progressively worsening side effects including severe fatigue, shortness of breath, insomnia, decreased appetite, headaches, dizziness and balance problems and pancytopenia. Therefore, the treatment was stopped after 16 weeks, at which time HCV RNA was undetectable. He developed blisters on the dorsal hands at 1 month after stopping therapy, and at 6 months HCV was found to have relapsed. PCT relapse was treated with low-dose HCQ (100 mg twice weekly), to which he was noncompliant. At age 64, he completed 12 weeks' treatment with sofosbuvir and simeprevir. Before being lost to follow-up, HCV RNA was undetectable at 8 and 12 weeks after starting therapy.
Patient 11
Patient was a white male who developed PCT at the age of 48 years with blisters on the dorsal hands. He was known to have chronic HCV genotype 1 infection for many years, which was acquired from intravenous drug use. He was treated elsewhere by phlebotomy and the blisters resolved. PCT relapsed on 5 different occasions and was treated successfully each time by phlebotomy. He decreased the use of alcohol from about 12 beers daily to 3 and continued to smoke a half pack of cigarettes per day since age 16. At age 59, when he had mild blistering on the dorsal hands, he was treated with sofosbuvir and ledispavir for a total duration of 12 weeks. He achieved SVR, and PCT resolved and has remained in remission for more than 1 year.
Patient 12
Patient was a white male who was found to have HCV genotype 4 infection at the age of 60 years and was treated unsuccessfully with PEGIFN and ribavirin, which was discontinued after 6 months due to poor tolerance and anemia. A liver biopsy at age 66 years showed cirrhosis. At age 67, he first developed blistering skin lesions on the dorsal hands, with elevated urine porphyrins at 2,623 nmol/L (uroporphyrin 52%, heptacarboxyl porphyrin 31%, hexacarboxyl porphyrins 5%, pentacarboxyl porphyrins 7% and coproporphyins 5%) and plasma porphyrins of 5.2 μg/dL. The level of HCV RNA was 410 million copies/mL. After completing 24 weeks of treatment with sofosbuvir and ledispavir, a SVR was achieved. Skin lesions resolved during treatment and plasma porphyrins have so far decreased to 2.3 μg/dL.
Patient 13
Patient was a white male who was found at the age of 48 years to have chronic HCV genotype 3a infection, which was acquired previously from intravenous drug use. Other susceptibility factors for PCT included heavy alcohol use and smoking. At age 51, he developed blistering on the dorsal hands, and later on the scalp and feet. He improved several times without treatment when he stopped drinking. He has been abstinent since age 62, but continues to smoke. He avoided sunlight and had no blisters after age 63, although urine and plasma porphyrins remained mildly elevated, with a predominance of uroporphyrin and heptacarboxyl porphyrin. Ultrasound showed coarsened hepatic echotexture without splenomegaly, and liver biopsy showed bridging fibrosis. He was treated with sofosbuvir, daclatasvir and ribavirin at age 64. Although treatment was shortened to 10 weeks due to a severe rash, SVR and normal porphyrin levels were achieved, and have persisted after 6 months.
DISCUSSION
These 13 cases of PCT associated with chronic HCV infection and other coexisting susceptibility factors were managed before and during a period when treatment of chronic HCV is improving dramatically. In the era of interferon treatment of HCV, it has been traditional to treat PCT first and HCV later, not only because PCT is generally more symptomatic and readily treated but also the treatment duration was shorter with a better response rate and fewer side effects. 1, 14 In addition, response to interferon-based therapies was reported to be better after reduction of iron overload by phlebotomy. 12 In this case series of 13 patients, we describe effects and interactions of treatments for these 2 conditions. Four courses of interferon and ribavirin-based therapy in 3 patients were associated with recurrence of PCT, as observed in earlier reports. [16] [17] [18] [19] Ribavirin can cause hemolytic anemia, which may reduce hepcidin levels and lead to increased iron absorption and contribute to hepatic iron overload, 20, 21 and interferon may increase oxidative stress in hepatocytes, resulting in increased generation of uroporphobilinogen decarboxylase inhibitor.
Low-dose HCQ was successful in preventing the recurrence of PCT during 5 courses of HCV therapy (all including ribavirin and 3 including interferon) that achieved sustained viral responses. This treatment combination has, to our knowledge, not been previously reported to be useful in patients with both conditions, and warrants further study for confirmation. Use of phlebotomies to prevent the recurrence of PCT during regimens including interferon or ribavirin is likely to be problematic because these agents often cause anemia. Although in the future these regimens are likely to be used less often than direct acting antivirals (DAA) for treating HCV, cost considerations may favor their use, particularly in treating certain HCV genotypes.
The newer DAA-based regimens for the treatment of HCV are shorter, safer and much more effective than interferon-based regimens, with SVR rates of greater than 95%. 15 Therefore, initial treatment of both HCV and PCT with a DAA-based regimen is appealing. In 1 reported case, remission of PCT was achieved with boceprevir-based triple therapy. 22 In this series, 2 patients were treated for HCV using DAA when the PCT was active, and porphyrins decreased significantly in 1 patient and completely normalized in the other. Susceptibility factors in addition to HCV are almost always identifiable in these patients, 6 as in all but 1 patient in this series. Given the heterogeneity of susceptibility factors, it remains unclear how often the cure of an HCV infection will lead to remission of PCT, and whether remission is achieved as rapidly as with phlebotomy or low-dose HCQ.
Strengths of this report include a large number of patients with well-documented PCT, who were observed as carefully as possible to document remission of both PCT and HCV. A limitation is that the patients were not in a study to assess the treatment of HCV, although most participated in a study comparing time to remission with HCQ or phlebotomy. 7 By chance, none of the patients had heterozygous UROD mutations, but it is unlikely that the presence of this susceptibility factor would alter response to treatment of HCV.
CONCLUSIONS
Our experience demonstrates (1) that treatment regimens that includes PEGIFN and ribavirin, which remain important in economically disadvantaged countries, can worsen PCT or be associated with the onset of PCT, (2) continuing low-dose HCQ treatment may be a good option for preventing worsening of PCT during such regimens, (3) based on limited experience, DAAbased HCV therapy may not be associated with onset or worsening of PCT and (4) treatment with DAA may be as safe and effective as primary treatment for PCT, when associated with HCV. But treatment of PCT by phlebotomy or low-dose HCQ remain highly effective and with comparable times to remission. 7 Therefore, further studies, such as those initiated by the Porphyrias Consortium, are needed to establish whether effectiveness and time to remission of PCT with DAA treatment is noninferior to and as durable as with phlebotomy or lowdose HCQ.
